Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Multiplex Assays Market to be Worth $6.80 Billion by 2031 - Exclusive Report by…

In a single reaction, multiplex immunoassays measure a large number of various analytes. This is especially useful when only a few samples are collected for examination. Multiplex assays refer to laboratory techniques that allow the simultaneous detection and measurement of multiple analytes or targets within a single sample. These assays are widely used in various scientific and clinical applications due to their efficiency, cost-effectiveness, and ability to generate a wealth of data from a…

IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August…

If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call. If you are unable to join us live, a recording of the call will be available on our website athttps://investors.imcannabis.com/within 24 hours after the call. Link for the to register for the zoom call:https://us02web.zoom.us/webinar/register/WN_W9nYbBB4R7CREuqN9dGOag About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE:...

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides…

ZYNLONTA ®net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025Full enrollment in LOTIS-5 trial expected before year-end 2024Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug.06, 2024(GLOBE NEWSWIRE) -- ADC Therapeutics SA...

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 06 August 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…

Tecan schedules conference call on August 13th to discuss half year 2024…

Tecan schedules conference call on August 13 thto discuss half year 2024 financial results Männedorf, Switzerland, August 6, 2024 –The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2024 on Tuesday, August 13th, 2024 at 08:30 CEST. The results will be published on August 13th, 2024 at 6:00 CEST.The conference call will be audio-webcast with synchronized presentation slides. The webcast and a...

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate…

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateAnnounced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront and total potential milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial in Alzheimer's disease (AD) on track with enrolment expectationsACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson's disease (PD) on track for safety and...

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their…

LONDON and NEW YORK, Aug.06, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key European Patent entitled: “Compositions...

MolecuLight's Profound Impact on Wound Healing Highlighted in Breaking Clinical…

When comparing the outcomes of patients that were treated per standard of care approach alone with those in which MolecuLight real-time fluorescence was integrated into that care, those in the MolecuLight-imaged group saw 71% more wounds healed by 12 weeks, healed 28% faster, and were 1.8 times more likely to heal their wound by 12-weeks. The researchers also investigated the incidence of severe infection complications including cellulitis, osteomyelitis, gangrene, sepsis, and wound-related…

California Tree Free Nappies Era Begins; Soft N Dry Introduces New ecoSoft Brand

The ecoSoft disposable nappies brand stands out for its exceptional softness and dryness, significantly reducing environmental impact by eliminating the use of tree fibre. Annually, an estimated 10 million trees are used globally to manufacture disposable baby nappies. ecoSoft's entry into the California market, which boasts a population of over 39 million people and one of the world's largest economies, marks a significant milestone. California often sets trends in consumer eco products…

Regenerative Medicine Market to Reach $531.7 Billion, Globally, by 2033 at 32.4%…

Request Sample of the Report on Regenerative Medicine Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/391 Request Sample of the Report on Regenerative Medicine Market Forecast 2033 -https://www.alliedmarketresearch.com/request-sample/391 Prime determinants of growth Rise in incidences of chronic diseases and increase in geriatric population are the major factors that drive the growth of the regenerative medicine market growth. However, high costs of...

Release Therapeutics Secures CHF 3.3 Million in Seed Funding

The funding follows the Company's first preclinical results in metachromatic leukodystrophy and will be invested in studies in non-human primates MLD is a rare genetic disorder of the nervous system stemming from a deficiency in the lysosomal enzyme, arylsulfatase A (ARSA); it is most common in toddlers aged 12 to 20 months (late infantile MLD). Tragically, this condition is usually diagnosed after symptoms appear, making it too late to treat with available therapies and resulting in most...

BioInnovation Institute enters into a collaboration with MIT and UNC to support…

The Bio Studio project, named Pivot, will focus on how mucus can combat antibiotic resistance. The project aims to leverage the mucus barrier, an essential component of the innate immune system, to address the unmet medical needs of chronic lung diseases. The project will be led by Principal Investigators, Professor Katharina Ribbeck and Associate Professor Matthew Wolfgang. The Bio Studio project, named Pivot, will focus on how mucus can combat antibiotic resistance. The project aims to...

VALNEVA - Declaration of shares and voting rights: July 31, 2024

VALNEVADeclaration of shares and voting rightsJuly 31, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: August 6, 2024 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the change...

The Adecco Group: Q2 2024 Results

Denis Machuel, Adecco Group CEO, commented: Denis Machuel, Adecco Group CEO, commented: "The Group gained a further +375 bps market share in the second quarter, on top of the +775 bps gain in the prior year period. Revenues eased on an organic basis reflecting continued market challenges, although pricing remained firm. We delivered above-target G&A cost savings, supporting a robust EBITA margin, and importantly, delivered improved cash flow through good working capital…

CARBIOS and FCC Environment announce joint project to establish UK-based PET…

Clermont-Ferrand (France) and Doncaster, England (UK), Tuesday 6 August 2024 (06.45 CEST). CARBIOS,(Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, andFCCEnvironment UK (“FCC”), one of the UK's leading recycling and waste management companies, have signed a Letter of Intent (LOI) to jointly study the implementation of a UK-based plant using CARBIOS' PET biorecycling...

Terumo Establishes Corporate Venture Capital "Terumo Ventures"

Terumo has been building relationships with medtech start-ups by investing in venture capital funds in the United States and China since 2013. With the establishment of the CVC, the company will further increase its agility in identifying, evaluating, and executing venture investments, while accelerating the speed of acquiring cutting-edge technologies and developing a robust M&A target pipeline for future growth. Terumo has been building relationships with medtech start-ups by investing…

ONWARD® Medical Reaffirms 2024 Strategic Priorities and Releases Unaudited Q2…

Company expects to commercialize the investigational ARC-EX ®System in Q4 2024 and has commenced launch preparations Company preparing to initiate global pivotal trial for investigational ARC-IM ®Therapy to address blood pressure instability after spinal cord injuryCompany expects to advance clinical and development activities for its unique ARC-BCI ™brain-computer interface therapy EINDHOVEN, the Netherlands, Aug.05, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V...

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Aug.05, 2024(GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 07/31/2024100,093,63588,029,164For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia...

Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with…

Adding Ultimovacs' cancer vaccine UV1 to checkpoint inhibitor pembrolizumab did not meet primary or secondary endpoints in patients with metastatic or recurrent head and neck squamous cell carcinomaUV1 continues to show a positive safety profile in line with other UV1 studies with similar events observed in the control arm and good tolerabilityAs previously communicated, financial runway secured until Q4 2025 beyond expected topline results from DOVACC Phase II study in 1H2025Within the...

Transparency Notification from Shareholders

PRESS RELEASE REGULATED INFORMATION5 August 2024, 06 pm CESTTransparency Notification from ShareholdersGhent, Belgium – 5 August 2024 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the party listed below, notifying the number of voting rights attached to the shares mentioned next…

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024

NTG Nordic Transport Group publishes interim report for H1 2024

Bone Conduction Headphones Market Size to Grow USD 3671.9 Million by 2030 at a…

Single-Cell Analysis Market worth $6.9 billion by 2029 driven by Technological…

Multiplex Assays Market to be Worth $6.80 Billion by 2031 - Exclusive Report by…

IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August…

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides…

Novo Nordisk A/S - share repurchase programme

Tecan schedules conference call on August 13th to discuss half year 2024…

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate…

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their…

MolecuLight's Profound Impact on Wound Healing Highlighted in Breaking Clinical…

California Tree Free Nappies Era Begins; Soft N Dry Introduces New ecoSoft Brand

Regenerative Medicine Market to Reach $531.7 Billion, Globally, by 2033 at 32.4%…

Release Therapeutics Secures CHF 3.3 Million in Seed Funding

BioInnovation Institute enters into a collaboration with MIT and UNC to support…

VALNEVA - Declaration of shares and voting rights: July 31, 2024

The Adecco Group: Q2 2024 Results

CARBIOS and FCC Environment announce joint project to establish UK-based PET…

Terumo Establishes Corporate Venture Capital "Terumo Ventures"

ONWARD® Medical Reaffirms 2024 Strategic Priorities and Releases Unaudited Q2…

Monthly information on share capital and company voting rights

Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with…

Transparency Notification from Shareholders